Lung Cancer

Phase 3 data also show an improvement in deterioration-free survival with TTFields and best supportive care in those with NSCLC and brain metastases.

Long-term data from the CheckMate 9LA trial support nivolumab/ipilimumab plus chemotherapy as frontline treatment for metastatic NSCLC.

Most treatment-related adverse effects reported with CAN-2409 plus valacyclovir in a phase 2 trial were grade 1 or 2.

CheckMate 77T trial saw an EFS improvement with neoadjuvant nivolumab in stage III N2 and stage III non-N2 non–small cell lung cancer.

Phase 2 data support further evaluation of datopotamab deruxtecan in patients with non–small cell lung cancer and brain metastases.

The CheckMate 816 trial reinforced the EFS data of nivolumab plus chemotherapy in resectable NSCLC.

Final DFS results from IMpower010 show consistent survival when adjuvant atezolizumab was used in stage IB to IIIA NSCLC.

Phase 2 data also show activity in diseases with resistance mutations such as G2032R with taletrectinib.

Either telehealth or in-person recipes of palliative care did not impact the quality of life outcomes for patients with advanced non–small cell lung cancer.

Osimertinib may become a new standard of care for those with EGFR-mutant NSCLC, according to Suresh S. Ramalingam, MD, FACP, FASCO.

Data from the ADRIATIC trial show consistent PFS and OS benefits with durvalumab across predefined limited-stage small cell lung cancer subgroups.

A PFS benefit with adagrasib was observed across all key patient subgroups in the phase 3 KRYSTAL-12 trial.

Subcutaneous amivantamab proved noninferior vs intravenous administration in EGFR-mutated non–small cell lung cancer.

Updated MARIPOSA results found improves progression-free survival in patients with high-risk EGFR-mutant advanced non-small cell lung cancer when treated with amivantimab/lazertinib.

Expert perspectives on next-generation sequencing for patients with non–small cell lung cancer, highlighting challenges and the differences between RNA and DNA testing.

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Rian M. Hasson Charles, MD, MPH, FACS, has a first-of-its-kind role at Brigham Women’s Hospital that will focus on health equity.

Dr. Gregory Gan presents Case 4, featuring a 71-year-old diagnosed with Stage IIIA NSCLC experiencing pneumonitis following Chemo-IO treatment, prompting a discussion with expert insight on the monitoring and management of this condition.

Dr. Gregory Gan introduces Case 2, involving a 70-year-old former smoker with Stage IIIB NSCLC and a PD-L1 level of 10%, prompting discussion with emphasis on the importance of shared decision-making with the patient and their caregivers.

Dr. Gregory Gan introduces Case 2, featuring an 82-year-old former smoker with poorly differentiated lung adenocarcinoma and a PD-L1 level of 85%, initiating a conversation on the role of a multidisciplinary approach to treatment and consideration factors for surgical and radiotherapy interventions.

Gregory Gan, MD, presents Case 1 involving a 72-year-old former smoker with Stage-IIIA NSCLC and a PD-L1 level of 90%, initiating a discussion on the treatment and management of the case.

Results from a phase 2 trial support the safety and tolerability of VGT-309 in patients with suspected lung cancer who undergo standard-of-care surgical resection.

University of Kansas experts offer guidance for community practitioners treating non-small cell lung cancer (NSCLC).

Dr. Reddy offers expert insights on employing concurrent immunotherapy with chemoradiotherapy, discussing the approach's role and drawing from recent data, such as results from the KEYNOTE-799, PACIFIC-6, and DOLPHIN studies, to inform treatment strategies.

A group of experts in oncology investigates the feasibility of combination adjuvant immunotherapy in NSCLC consolidation, assessing the utilization of multiple immune checkpoint inhibitors and scrutinizing the rationale, with a focus on findings from the COAST study and PACIFIC-8 studies.

Vinay Raja, MD, explores the management of patients with Stage-III disease and actionable EGFR/ALK aberrations, as well as the treatment approach for patients with PD-L1 <1%.

A panel of oncology experts examine the role of consolidation immunotherapy in patients receiving concurrent chemoradiotherapy for unresectable Stage-III NSCLC, discussing 5-year survival outcomes from the PACIFIC trial, the impact on institutional treatment approaches, criteria for selecting patients for consolidation durvalumab, the significance of baseline scans, as well as exploring real-world evidence on consolidation durvalumab.

Krishna Reddy, MD, PhD, explores the roles of sequential and concurrent chemoradiotherapy (sCRT and cCRT) in patients with unresectable stage III NSCLC, delving into considerations for selecting between the two approaches and examining potential variations in treatment based on factors such as age, performance status (PS), or comorbidities.

Gregory Gan, MD, briefly outlines the available treatment strategies for stage III unresectable NSCLC, and Alykhan Nagji, MD explores the characterization of patients with unresectable stage III NSCLC, underscoring the crucial role of accurate staging in guiding treatment decisions.

Oncology experts from the University of Kansas discuss treatment strategies for both resectable and unresectable non-small cell lung cancer (NSCLC) following progression on adjuvant immunotherapy, providing valuable insights into navigating the challenges posed by this evolving clinical scenario.